Navigation Links
Questcor Pharmaceuticals Expands Repurchase Program
Date:5/16/2012

, were driven by our belief that there is a substantial difference between the intrinsic value and the market value of our common stock.  This belief is based on several factors, including the following:

  • Net sales and earnings per share for the quarter ended March 31, 2012 increased by more than 60% over the quarter ended September 30, 2011 – the quarter prior to the initial expansion of our nephrotic syndrome sales force from 5 to 28 Acthar specialists;
  • We have gained greater confidence in the long-term potential for Acthar in the treatment of patients suffering from nephrotic syndrome;
  • We are in the process of further expanding our nephrology and neurology sales forces, and similar expansions in the past have resulted in significant growth in net sales; and
  • We are preparing to launch a pilot effort in rheumatology, a therapeutic area in which Acthar has a number of approved indications with sizeable markets with patients with high unmet needs.

From the beginning of 2008 through May 15, 2012, we have returned approximately 78% of our operating cash flow to shareholders by repurchasing stock at an average price of $12.26 per share.  During that period, we have also been able to fund other important initiatives, including the significant expansion of our research and development activities.  We have also continued our patient-support programs, providing $150 million in free Acthar through March 31, 2012. "

Stock repurchases under this program may be made through open market or privately negotiated transactions in accordance with all applicable laws, rules and regulations. The transactions may be made from time to time and in such amounts as management deems appropriate. The number of shares to be repurchased and the timing of repurchases will be based on several factors, including the price of the Company's common stock, general business and market condi
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
4. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
5. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
6. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
7. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
8. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
9. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
10. Syndax Pharmaceuticals Appoints Arlene Morris as CEO
11. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Follow us ... to revolutionize the world has attracted diverse players ... small start-ups. The early years of nanotechnology development ... due to the high risks involved, which deterred ... for this evolving technology have been growing over ...
(Date:9/19/2014)... 19, 2014 Pfenex Inc. (NYSE MKT: PFNX), ... high-value and difficult to manufacture proteins including biosimilar therapeutics, ... 21 st Annual NewsMakers in the Biotech Industry ... Bertrand Liang , chief executive officer of Pfenex, will ... business strategy on Friday, September 26, 2014 at 10:00 ...
(Date:9/19/2014)... 19, 2014 ... ) has announced the addition of the  "Micro ... to their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... of the fastest-growing segments in the chromatography market. ... 2013, and expected to reach $2.0 billion by ...
(Date:9/18/2014)... 2014 HealthTronics, Inc ., ... radiology products and services, announced that a poster ... cryoablation) versus external beam radiotherapy (EBRT) is being ... Urological Association (MAAUA) Annual Meeting in Baltimore, Maryland ... of Cryosurgery and External Beam Radiation as Treatments ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... Boston Scientific,Corporation (NYSE: BSX ) today announced financial ... as guidance for net sales and,earnings per share (EPS) for ... -- Reported net sales of $1.978 billion and adjusted ... market leadership -- Achieved worldwide cardiac rhythm management (CRM) ...
... Holding Company to Strengthen ... Acquires Research and Product Development Company to Expedite Product ... ... at 8:00 am E.T., NEW YORK, Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, ...
... $165 Million Line of Credit to ... Amylin, ... ) and Eli Lilly and Company (NYSE: LLY ),today announced they have ... if approved, would,become the first once weekly therapy to treat type 2 diabetes. ...
Cached Biology Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27American Oriental Bioengineering Completes Two Acquisitions 2American Oriental Bioengineering Completes Two Acquisitions 3American Oriental Bioengineering Completes Two Acquisitions 4Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 2Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 3
(Date:9/18/2014)... 2014 New research into the Crimean-Congo hemorrhagic fever ... hemorrhagic disease in humans similar to that caused by ... infection. This discovery has the potential to lead to ... , The research, reported in a paper published ... conducted by scientists at the Texas Biomedical Research Institute ...
(Date:9/18/2014)... of Americans to undertake jaunts into the countryside each year ... within a century, according to new research. , Climate change ... United States as summer temperatures linger later into the year, ... and Biogeography . For instance, the paper birch a ... Hampshire could change color one to three weeks later ...
(Date:9/18/2014)... and ethnic groups describe losing eyesight as potentially ... more so than other conditions including: loss of ... 49% of non-Hispanic whites, 43% of Asians and ... ailment is the worst that could happen to ... AIDS/HIV. Hispanics and Asians ranked cancer first ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... Heart patients who can,t tolerate the side effects ... to a new study by researchers from the Intermountain ... City. Researchers found that pitavastatin, a newer cholesterol-lowering ... and even death in up to 68 percent of ...
... has identified a protein that can change DNA topology, making DNA ... new insight about the role of the proteinknown as mini-chromosome maintenance ... Think about twisting one end of a rubber band while holding ... neatly twisted rope. But if you keep on turning, the twisted ...
... the greatest mysteries of modern coral reefs is how they ... long existed in the record of coral evolution. This ... sea level and changes in the Earth,s climate between 1 ... "old" corals went extinct, and the modern reef corals emerged. ...
Cached Biology News:Researchers find alternative cholesterol-lowering drug for patients who can't tolerate statins 2Protein abundant in cancerous cells causes DNA 'supercoiling' 2University of Miami geologists to address the mystery of an evolution gap in reef corals 2
... Cell permeable fluorescent minor groove-binding probe ... of double-stranded DNA (preferentially to AT rich ... approximately 20 times greater than DAPI alone. ... ethidium bromide for staining DNA in agarose ...
... The 96 PW is an intelligent full ... washing all wells simultaneously. This instrument gives you ... and outstanding washing efficiency , Performance ... throughput and excellent wash efficiency. A dispense precision ...
... CE 4100 high pressure dual piston pump and ... for added flexibility. The system is ... unit, CE 4901., The CE 4901 PowerStream software ... with Windows 98 and 2000, offers the same ...
...
Biology Products: